Multidrug-resistant tuberculosis: This is the cost

Annals of the New York Academy of Sciences

Volumn 953, Issue , 2001, Pages 233-240

  Moore Gillon, John ^a  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

Clinical care costs; Economic impact of TB; Multidrug resistant tuberculosis; Public health

Indexed keywords

AMIKACIN; CAPREOMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ISONIAZID; PROTIONAMIDE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN;

CONFERENCE PAPER; COST OF ILLNESS; DRUG SENSITIVITY; ECONOMIC ASPECT; HUMAN; MULTIDRUG RESISTANCE; PUBLIC HEALTH; TUBERCULOSIS; TUBERCULOSIS CONTROL;

EID: 0035692692     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2001.tb11382.x     Document Type: Conference Paper

References (16)

1. Socio-economic impact of tuberculosis on patients and family in India
2. Economic impact of tuberculosis at the household level
3. The impact of drug resistance on the global tuberculosis epidemic
4. Causes and costs of hospitalisation of tuberculosis patients in the United States
5. Shifting the balance between in-patient and out-patient care for tuberculosis results in economic savings
6. Resource implications of multidrug resistant tuberculosis
7. A multi-institutional outbreak of highly drug-resistant tuberculosis
8. Chemotherapy and management of tuberculosis in the United Kingdom: Recommendations
9. Chemotherapy and management of tuberculosis in the United Kingdom: Recommendations
10. A clinical microbiological and economic analysis of a national UK service for the rapid molecular diagnosis of tuberculosis and rifampicin resistance in Mycobacterium tuberculosis
11. Tuberculosis in New York City - Turning the tide
12. The dilemma of MDR-TB in the global era
13. Rational "DOTS plus" for the control of MDRTB
14. Tuberculosis control strategies and utilitarianism